News
Proportion of adult managed care organizations with availability varied from 24 to 100 percent for SGLT2 inhibitors, 0 to 99 percent for GLP-1 receptor agonists.
The ongoing phase 2b SunRISe-1 study is assessing TAR-200 intravesical gemcitabine delivery in patients with BCG-unresponsive high-risk NMIBC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback